Febbo PG - Search Results

1

The V89L polymorphism in the 5alpha-reductase type 2 gene and risk of prostate cancer.

Febbo PG, Kantoff PW, Platz EA, Casey D, Batter S, Giovannucci E, Hennekens CH, Stampfer MJ. Febbo PG, et al. Cancer Res. 1999 Dec 1;59(23):5878-81. Cancer Res. 1999. PMID: 10606227 Clinical Trial.

2

A polymorphism of the 5 alpha-reductase gene and its association with prostate cancer: a case-control analysis.

Kantoff PW, Febbo PG, Giovannucci E, Krithivas K, Dahl DM, Chang G, Hennekens CH, Brown M, Stampfer MJ. Kantoff PW, et al. Among authors: febbo pg. Cancer Epidemiol Biomarkers Prev. 1997 Mar;6(3):189-92. Cancer Epidemiol Biomarkers Prev. 1997. PMID: 9138662

3

Debrisoquine hydroxylase (CYP2D6) and prostate cancer.

Febbo PG, Kantoff PW, Giovannucci E, Brown M, Chang G, Hennekens CH, Stampfer M. Febbo PG, et al. Cancer Epidemiol Biomarkers Prev. 1998 Dec;7(12):1075-8. Cancer Epidemiol Biomarkers Prev. 1998. PMID: 9865424

4

No association between the I105V polymorphism of the glutathione S-transferase P1 gene (GSTP1) and prostate cancer risk: a prospective study.

Shepard TF, Platz EA, Kantoff PW, Nelson WG, Isaacs WB, Freije D, Febbo PG, Stampfer MJ, Giovannucci E. Shepard TF, et al. Among authors: febbo pg. Cancer Epidemiol Biomarkers Prev. 2000 Nov;9(11):1267-8. Cancer Epidemiol Biomarkers Prev. 2000. PMID: 11097238 No abstract available.

5

Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial.

Ross RW, Galsky MD, Febbo P, Barry M, Richie JP, Xie W, Fennessy FM, Bhatt RS, Hayes J, Choueiri TK, Tempany CM, Kantoff PW, Taplin ME, Oh WK. Ross RW, et al. Cancer. 2012 Oct 1;118(19):4777-84. doi: 10.1002/cncr.27416. Epub 2012 Jan 26. Cancer. 2012. PMID: 22282219 Free PMC article. Clinical Trial.

6

No association between a polymorphic variant of the IRS-1 gene and prostate cancer risk.

Fall K, Stark JR, Mucci LA, Chan J, Stampfer MJ, Kurth T, Febbo PG, Kantoff P, Ma J. Fall K, et al. Among authors: febbo pg. Prostate. 2008 Sep 15;68(13):1416-20. doi: 10.1002/pros.20797. Prostate. 2008. PMID: 18615538 Free PMC article.

7

Neoadjuvant doxil chemotherapy prior to androgen ablation plus radiotherapy for high-risk localized prostate cancer: feasibility and toxicity.

Oh WK, Kaplan ID, Febbo P, Prisby J, Manola J, Kaufman DS, Kantoff PW. Oh WK, et al. Am J Clin Oncol. 2003 Jun;26(3):312-6. doi: 10.1097/01.COC.0000020921.08768.1F. Am J Clin Oncol. 2003. PMID: 12796607 Clinical Trial.

8

Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study.

Taplin ME, George DJ, Halabi S, Sanford B, Febbo PG, Hennessy KT, Mihos CG, Vogelzang NJ, Small EJ, Kantoff PW. Taplin ME, et al. Among authors: febbo pg. Urology. 2005 Aug;66(2):386-91. doi: 10.1016/j.urology.2005.03.040. Urology. 2005. PMID: 16098367

9

Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate.

Tay MH, Kaufman DS, Regan MM, Leibowitz SB, George DJ, Febbo PG, Manola J, Smith MR, Kaplan ID, Kantoff PW, Oh WK. Tay MH, et al. Among authors: febbo pg. Ann Oncol. 2004 Jun;15(6):974-8. doi: 10.1093/annonc/mdh221. Ann Oncol. 2004. PMID: 15151957 Free article.

10

Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.

Atkins M, Regan M, McDermott D, Mier J, Stanbridge E, Youmans A, Febbo P, Upton M, Lechpammer M, Signoretti S. Atkins M, et al. Clin Cancer Res. 2005 May 15;11(10):3714-21. doi: 10.1158/1078-0432.CCR-04-2019. Clin Cancer Res. 2005. PMID: 15897568

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

97 results

Search Page

Filters